Growth failure associated with the use of high dose prozac (fluoxetine hydrochloride) in a patient with type 1 diabetes mellitus

Journal of Pediatric Endocrinology and Metabolism

Volumn 12, Issue 3, 1999, Pages 467-469

  Frank, Graeme R ^a   Navon, Richard E ^b  

^a SCHNEIDER CHILDREN'S HOSPITAL   (United States)

^b Child Adol Psychiatrist Priv P   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOXETINE;

ADOLESCENT; ARTICLE; CASE REPORT; DIABETIC KETOACIDOSIS; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; GROWTH DISORDER; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MALE;

EID: 0033067375     PISSN: 0334018X     EISSN: None     Source Type: Journal    
DOI: 10.1515/JPEM.1999.12.3.467     Document Type: Article

References (4)

1. Geller DA, Biederman J, Reed ED, Spencer T, Wilens TE. Similarities in response to fluoxetine in the treatment of children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 1995; 34: 36-44.
2. Birmaher B, Waterman GS, Ryan N, Cully M, Balach L, Ingram J, Brodsky M. Fluoxetine for childhood anxiety disorders. J Am Acad Child Adolesc Psychiatry 1994; 33: 993-999.
3. Bouvard M, Dugas M. Fluoxetine in obsessive compulsive disorder in adolescents. Int Clin Psychopharmacol 1993; 8: 307-310.
4. Riddle MA, Scahill L, King RA, Hardin MT, Anderson GM, Ort SI, Smith JC, Leckman JF, Cohen DJ. Double-blind, crossover trial of fluoxetine and placebo in children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 1992; 31: 1062-1069.